I've been trying to wade through the Proprius buyout. Basically, as I understand it, Cyprus is willing to pay Michael Walsh (Not Michael Lee, sorry dude) almost 60M the moment phase lll Indaflex starts. Perhaps Proprius has an RA medication they've recently acquired but not in clinical trial. Thus, considering ALRX has a market cap of only 12M and Proprius' existence was, at least recently, based onnothing but Indaflex, things ought to look pretty good, pretty soon. And, the TSX listing is forthcoming, also considered good. It appears that it will be in Mr. Walsh's best interest to start Phase lll and pocket the extra 20M. So, we'll see if all these med-tech people know what they're doing.
I have long been concerned that, although the ALRX strategy of partnering to get drugs on the market is good, the partners have no reason to be interested in ALRX stockholders. Now, somewhat indirectly, the 20M carrot is being dangled in front of Proprius that will provide benefits to patient stockholders (I'm at 4 years and counting). Hopefully, problem solved...... Comments?
